whoa. whoa. whoa.

You're being directed to the ELOCTATE Healthcare Professional website. If you're okay with that, we're okay with that.

Come back soon!

Home Hero

Gabriel tells his own story

Gabriel had a rough time growing up with hemophilia. But switching to ELOCTATE and reducing his infusions helped him to focus on making his healthcare a priority. Now he has bleed and joint bleed protection* he can count on and feels ready for what's next.

*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.


What do you like about working out?

The routine. It just makes me feel empowered and disciplined.

What got you into fitness?

It's relatively new for me. As a kid I loved football, but that didn't last long with my Hemophilia. My teen years were rocky and focusing on my health and wellbeing has me hopeful about the future.

So, you've got big plans for the future?

Oh yeah. I want to go camping, fishing, hiking—all that stuff. But I also want to be active when I'm older and have kids and grandkids to play with.

Why did you switch to ELOCTATE?

The idea of an extended half-life treatment that allowed me to infuse less often while getting the bleed and joint bleed protection I desired piqued my interest. The doctor empowered me to make the decision. So, I decided to switch.

And how has it gone?

It was an excellent choice both for my health and independence. Not only am I happy with ELOCTATE, but I also worked with my healthcare team to start taking charge of my joint health.

Note: Patient stories reflect the real-life experiences of persons diagnosed with hemophilia A who have been prescribed ELOCTATE. However, individual experiences may vary. Patient stories are not necessarily representative of what another person using ELOCTATE may experience. Talk to your healthcare provider about what's right for you. ELOCTATE Peers have been compensated for sharing their stories.

The recommended starting regimen is 50 IU/kg every 4 days as directed by your doctor. In children under 6 years of age, the recommended starting regimen is 50 IU/kg administered twice weekly. The regimen can be adjusted based on your body's individual response.




Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.

Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.

Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.

If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.

These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.


ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.



Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078